Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-17

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study used 3 different formulations of tetravalent CYD dengue vaccine.

The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue vaccine administered at Month 0 and Month 6.

The secondary objectives were:

* To evaluate the safety of the 3 formulations of tetravalent CYD dengue vaccine.
* To describe the neutralizing antibody responses to each of the 3 vaccine formulations.
* To describe vaccine viremia after the first and second dose of each of the 3 vaccine formulations in a subset of participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

NCT00740155

Dengue Virus Dengue Fever Dengue Hemorrhagic Fever +1 more

COMPLETED PHASE2

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

NCT01134263

Dengue Fever Dengue Hemorrhagic Fever

COMPLETED PHASE3

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

NCT01550289

Dengue Dengue Fever Dengue Hemorrhagic Fever

COMPLETED PHASE2

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

NCT02741128

Dengue Fever Dengue Hemorrhagic Fever Human Immunodeficiency Virus

COMPLETED PHASE2

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All participants provided blood samples for immunogenicity assessments, while vaccine viremia was assessed in a subset of participants in each group.

Safety was assessed in all participants as follows: solicited adverse event (AE) prelisted in the diary card were collected for 7 days after vaccination for solicited injection site reactions and 14 days for solicited systemic reactions , unsolicited AEs were collected for 28 days after vaccination, and serious adverse event (SAE) information collected throughout the study up to 6 months after vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dengue Fever Dengue Hemorrhagic Fever Dengue Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CYD Dengue Vaccine 5555 Formulation

Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.

Group Type EXPERIMENTAL

Tetravalent CYD Dengue Vaccine , 5555 formulation

Intervention Type BIOLOGICAL

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.

CYD Dengue Vaccine 5553 Formulation

Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.

Group Type EXPERIMENTAL

Tetravalent CYD Dengue Vaccine , 5553 formulation

Intervention Type BIOLOGICAL

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively

CYD Dengue Vaccine 4444 Formulation

Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.

Group Type EXPERIMENTAL

Tetravalent CYD Dengue Vaccine, 4444 formulation

Intervention Type BIOLOGICAL

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tetravalent CYD Dengue Vaccine , 5555 formulation

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.

Intervention Type BIOLOGICAL

Tetravalent CYD Dengue Vaccine , 5553 formulation

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively

Intervention Type BIOLOGICAL

Tetravalent CYD Dengue Vaccine, 4444 formulation

A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, as determined by medical history, clinical examination, and biological safety parameters.
* Aged 18 to 45 years on the day of inclusion.
* Provision of informed consent signed by the participant or another legally acceptable representative.
* For a woman of child-bearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, and until at least 4 weeks after the last study vaccination.
* Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria

* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.
* For a woman of child-bearing potential, known or suspected pregnancy or positive serum/urine pregnancy test.
* Breast-feeding woman.
* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
* Planned participation in another clinical trial during the present trial period.
* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term (at least 2 weeks within the previous 3 months) systemic corticosteroids therapy (at a dose of at least 10 mg). Topical steroids were allowed.
* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
* Current or past alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures.
* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response.
* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
* Planned receipt of any vaccine in the 4 weeks following each of the trial vaccinations.
* Human Immunodeficiency Virus (HIV), hepatitis B surface antigen, or hepatitis C virus seropositivity in blood sample taken at Screening.
* Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
* Clinically significant laboratory test abnormalities (as determined by the investigator) in blood sample taken at Screening.
* Previous residence in, travel or planned travel of more than 2 weeks during the study period to areas with high dengue infection endemicity.
* Reported history of flavivirus infection as reported by the participant.
* Previous vaccination against flavivirus diseases (including Japanese encephalitis, tick-borne encephalitis, and yellow fever).
* Flavivirus vaccination planned during the trial period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes